AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 182 filers reported holding AXSOME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $16,969 | +69.7% | 220 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $10,000 | +25.0% | 220 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $8,000 | -11.1% | 220 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $9,000 | +12.5% | 220 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $8,000 | +14.3% | 220 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $7,000 | -72.0% | 220 | -39.7% | 0.00% | -50.0% |
| Q2 2021 | $25,000 | +19.0% | 365 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $21,000 | -58.8% | 365 | -50.0% | 0.00% | 0.0% |
| Q4 2020 | $51,000 | +96.2% | 730 | +100.0% | 0.00% | -33.3% |
| Q3 2020 | $26,000 | -13.3% | 365 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $30,000 | +42.9% | 365 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $21,000 | -44.7% | 365 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $38,000 | +850.0% | 365 | +65.9% | 0.00% | – |
| Q3 2019 | $4,000 | -33.3% | 220 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $6,000 | – | 220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |